Indivior PLC (INDV)
NASDAQ: INDV · Real-Time Price · USD
9.16
+0.24 (2.69%)
Oct 29, 2024, 4:00 PM EDT - Market closed

Company Description

Indivior PLC, together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and co-occurring disorders in the United States, the United Kingdom, and internationally.

The company develops medicines to treat substance use disorders, serious mental illnesses, and opioid overdose.

Its core marketed products include SUBLOCADE and SUBUTEX PRO buprenorphine extended-release monthly injections; SUBOXONE, a buprenorphine and naloxone sublingual film; SUBOXONE, a buprenorphine and naloxone sublingual tablet; and SUBUTEX, a buprenorphine sublingual tablet for the treatment of opioid use disorder.

The company also offers OPVEE nasal spray for opioid overdose reversal; and PERSERIS extended-release injectable suspension for the treatment of schizophrenia in adults.

In addition, it is developing INDV-2000, a selective orexin-1 receptor antagonist that completed phase 1 clinical trial for the treatment of opioid use disorder (OUD); INDV-1000, a selective GABAb positive allosteric modulator, which is in pre-clinical development phase for the treatment of alcohol use disorder in collaboration with ADDEX therapeutics; INDV-6001, a buprenorphine-based long-acting injectable for the treatment of OUD in collaboration with Alar Pharmaceuticals Inc.; and CT-102, a digital therapeutic for the treatment of OUD in collaboration with Click Therapeutics.

Further, the company is developing INDV-5004, a drinabant injection to treat acute cannabinoid overdose.

It has a strategic partnership with Aelis Farma to develop AEF0117, a synthetic CB1 specific signaling inhibitor that is in phase 2B clinical trial for the treatment of cannabis use disorder.

The company was incorporated in 2014 and is headquartered in North Chesterfield, Virginia.

Indivior PLC
Indivior logo
Country United States
Founded 1994
Industry Drug Manufacturers - Specialty & Generic
Sector Healthcare
Employees 1,164
CEO Mark Crossley

Contact Details

Address:
10710 Midlothian Turnpike, Suite 125
North Chesterfield, Virginia 23235
United States
Phone 804 379 1090
Website indivior.com

Stock Details

Ticker Symbol INDV
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001625297
ISIN Number GB00BN4HT335
SIC Code 2834

Key Executives

Name Position
Mark Crossley Chief Executive Officer and Executive Director
Ryan Preblick Chief Financial Officer and Executive Director
Dr. Christian Heidbreder Chief Scientific Officer
Jason Thompson Vice President of Investor Relations
Cynthia Cetani Chief Integrity and Compliance Officer
Jeffrey W. Burris Chief Legal Officer
Jon Fogle Chief Human Resources Officer
Richard Simkin Chief Commercial Officer
Hillel West Chief Manufacturing and Supply Officer
Vishal Kalia SVice President of US Treatment Access, Support Programs and Business Insights and Chief Impact & Strategy Officer

Latest SEC Filings

Date Type Title
Oct 29, 2024 6-K Report of foreign issuer
Oct 24, 2024 S-8 POS Securities to be offered to employees in employee benefit plans, post-effective amendments
Oct 24, 2024 S-8 Securities to be offered to employees in employee benefit plans
Oct 24, 2024 6-K Report of foreign issuer
Oct 22, 2024 6-K Report of foreign issuer
Oct 17, 2024 SC 13D/A [Amend] General statement of acquisition of beneficial ownership
Oct 15, 2024 6-K Report of foreign issuer
Oct 15, 2024 6-K Report of foreign issuer
Oct 10, 2024 6-K Report of foreign issuer
Oct 8, 2024 6-K Report of foreign issuer